{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:25:24Z","timestamp":1789129524027,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic Myeloid Leukemia (CML) is a stem cell cancer that arises when t(9;22) translocation occurs in a hematopoietic stem cells. This event results in the expression of the BCR-ABL1 fusion gene, which codes for a constitutively active tyrosine kinase that is responsible for the transformation of a HSC into a CML stem cell, which then gives rise to a clonal myeloproliferative disease. The introduction of Tyrosine Kinase Inhibitors (TKIs) has revolutionized the management of the disease. However, these drugs do not seem to be able to eradicate the malignancy. Indeed, discontinuation trials (STIM; TWISER; DADI) for those patients who achieved a profound molecular response showed 50% relapsing within 12 months. We performed a comparative analysis on 15 CML patients and one B-ALL patient, between the standard quantitative reverse-transcriptase PCR (qRT\u2013PCR) and our genomic DNA patient-specific quantitative PCR assay (gDNA qPCR). Here we demonstrate that gDNA qPCR is better than standard qRT\u2013PCR in disease monitoring after an average follow-up period of 200 days. Specifically, we statistically demonstrated that DNA negativity is more reliable than RNA negativity in indicating when TKIs therapy can be safely stopped.<\/jats:p>","DOI":"10.1038\/s41419-018-0387-2","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T09:56:22Z","timestamp":1519984582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3794-4385","authenticated-orcid":false,"given":"Alessia","family":"Rainero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Angaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"D\u2019Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pirrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Micheloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Tarar\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Millefanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Maserati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Valli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0374-1536","authenticated-orcid":false,"given":"Orietta","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Buklijas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Michelato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Casalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Barlassina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Barcella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sirchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Piscitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-678X","authenticated-orcid":false,"given":"Massimo","family":"Caccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"387_CR1","first-page":"1013","volume":"27","author":"PC Nowell","year":"1961","unstructured":"Nowell, P. C. & Hungerford, D. A. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J. Natl. Cancer Inst. 27, 1013\u20131035 (1961).","journal-title":"J. Natl. Cancer Inst."},{"key":"387_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290\u2013293 (1973).","journal-title":"Nature"},{"key":"387_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/306239a0","volume":"306","author":"N Heisterkamp","year":"1983","unstructured":"Heisterkamp, N. et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306, 239\u2013242 (1983).","journal-title":"Nature"},{"key":"387_CR4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","volume":"88","author":"JV Melo","year":"1996","unstructured":"Melo, J. V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88, 2375\u20132384 (1996).","journal-title":"Blood"},{"key":"387_CR5","first-page":"1517","volume":"94","author":"RT Silver","year":"1999","unstructured":"Silver, R. T., et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood 94, 1517\u201336\u00a0(1999).","journal-title":"Blood"},{"key":"387_CR6","first-page":"253","volume":"91","author":"EKH Jabbour","year":"2016","unstructured":"Jabbour, E. K. H. Chronic Myeloid Leukemia: 2016 update on diagnosis, therapy, and monitoring. Am. J. Hematol. 91, 253\u2013265 (2016).","journal-title":"Am. J. Hematol."},{"key":"387_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561\u2013566 (1996).","journal-title":"Nat. Med."},{"key":"387_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med 348, 994\u20131004 (2003).","journal-title":"N. Engl. J. Med"},{"key":"387_CR9","doi-asserted-by":"publisher","first-page":"886-","DOI":"10.1038\/nrc3408","volume":"12","author":"T O\u2019Hare","year":"2012","unstructured":"O\u2019Hare, T., Zabriskie, M. S., Eiring, A. M. & Deininger, M. W. Pushing the limits of targeted therapy in chronic myeloid leukaemia (vol 12, pg 513, 2012). Nat. Rev. Cancer 12, 886- (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"387_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010).","journal-title":"Lancet Oncol."},{"key":"387_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross, D. M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515\u2013522 (2013).","journal-title":"Blood"},{"key":"387_CR12","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa, J. et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2, e528\u2013e535 (2015).","journal-title":"Lancet Haematol."},{"key":"387_CR13","doi-asserted-by":"publisher","first-page":"35293","DOI":"10.18632\/oncotarget.9182","volume":"7","author":"JC Chomel","year":"2016","unstructured":"Chomel, J. C. et al. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget 7, 35293\u201335301 (2016).","journal-title":"Oncotarget"},{"key":"387_CR14","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake, T. L. & Vetrie, D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129, 1595\u20131606 (2017).","journal-title":"Blood"},{"key":"387_CR15","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.4161\/cc.5.24.3573","volume":"5","author":"DJ Barnes","year":"2006","unstructured":"Barnes, D. J. & Melo, J. V. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 5, 2862\u20132866 (2006).","journal-title":"Cell Cycle"},{"key":"387_CR16","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","volume":"118","author":"M Tang","year":"2011","unstructured":"Tang, M. et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 118, 1622\u20131631 (2011).","journal-title":"Blood"},{"key":"387_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","volume":"119","author":"A Kumari","year":"2012","unstructured":"Kumari, A., Brendel, C., Hochhaus, A., Neubauer, A. & Burchert, A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 119, 530\u2013539 (2012).","journal-title":"Blood"},{"key":"387_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes, T. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108, 28\u201337 (2006).","journal-title":"Blood"},{"key":"387_CR19","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2009-11-255109","volume":"116","author":"M Sobrinho-Simoes","year":"2010","unstructured":"Sobrinho-Simoes, M. et al. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 116, 1329\u20131335 (2010).","journal-title":"Blood"},{"key":"387_CR20","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross, N. C., White, H. E., Muller, M. C., Saglio, G. & Hochhaus, A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26, 2172\u20132175 (2012).","journal-title":"Leukemia"},{"key":"387_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872\u2013884 (2013).","journal-title":"Blood"},{"key":"387_CR22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.18632\/oncoscience.65","volume":"1","author":"IS Pagani","year":"2014","unstructured":"Pagani, I. S. et al. Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in chronic myeloid leukemia. Oncoscience 1, 510\u2013521 (2014).","journal-title":"Oncoscience"},{"key":"387_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2353\/jmoldx.2009.080150","volume":"11","author":"E Mattarucchi","year":"2009","unstructured":"Mattarucchi, E. et al. Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. J. Mol. Diagn. 11, 482\u2013487 (2009).","journal-title":"J. Mol. Diagn."},{"key":"387_CR24","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller, M. C. et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23, 1957\u20131963 (2009).","journal-title":"Leukemia"},{"key":"387_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/gcc.20568","volume":"47","author":"E Mattarucchi","year":"2008","unstructured":"Mattarucchi, E. et al. Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. Genes. Chromosomes Cancer 47, 625\u2013632 (2008).","journal-title":"Genes. Chromosomes Cancer"},{"key":"387_CR26","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1080\/15384101.2015.1006053","volume":"14","author":"G Porta","year":"2015","unstructured":"Porta, G., Pagani, I. S. & Pirrone, C. gDNA Q-PCR for clinical monitoring of CML. Cell Cycle 14, 3659\u20133660 (2015).","journal-title":"Cell Cycle"},{"key":"387_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev.cb.11.110195.000343","volume":"11","author":"SJ Morrison","year":"1995","unstructured":"Morrison, S. J., Uchida, N. & Weissman, I. L. The biology of hematopoietic stem cells. Annu. Rev. Cell Dev. Biol. 11, 35\u201371 (1995).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"387_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jtbi.2005.03.033","volume":"237","author":"C Colijn","year":"2005","unstructured":"Colijn, C. & Mackey, M. C. A mathematical model of hematopoiesis\u2014I. Periodic chronic myelogenous leukemia. J. Theor. Biol. 237, 117\u2013132 (2005).","journal-title":"J. Theor. Biol."},{"key":"387_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/scd.2008.0143","volume":"18","author":"A Marciniak-Czochra","year":"2009","unstructured":"Marciniak-Czochra, A., Stiehl, T., Ho, A. D., Jager, W. & Wagner, W. Modeling of asymmetric cell division in hematopoietic stem cells\u2014regulation of self-renewal is essential for efficient repopulation. Stem Cells Dev. 18, 377\u2013385 (2009).","journal-title":"Stem Cells Dev."},{"key":"387_CR30","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor, F. et al. Dynamics of chronic myeloid leukaemia. Nature 435, 1267\u20131270 (2005).","journal-title":"Nature"},{"key":"387_CR31","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1158\/0008-5472.CAN-15-2069","volume":"76","author":"B Werner","year":"2016","unstructured":"Werner, B. et al. The cancer stem cell fraction in hierarchically organized tumors can be estimated using mathematical modeling and patient-specific treatment trajectories. Cancer Res. 76, 1705\u20131713 (2016).","journal-title":"Cancer Res."},{"key":"387_CR32","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","volume":"30","author":"S Branford","year":"2012","unstructured":"Branford, S. et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J. Clin. Oncol. 30, 4323\u20134329 (2012).","journal-title":"J. Clin. Oncol."},{"key":"387_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford, S. et al. Prognosis for patients with CML and>10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124, 511\u2013518 (2014).","journal-title":"Blood"},{"key":"387_CR34","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin, D. et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. 30, 232\u2013238 (2012).","journal-title":"J. Clin. Oncol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0387-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:46:33Z","timestamp":1671536793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0387-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0387-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"349"}}